Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04617522 · ClinicalTrials.gov registry record · Phase 1
Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
A Phase 1 study of Liver Failure and Advanced or Metastatic Solid Tumor, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 13
- Study locations
NCT04617522 is a Phase 1 study of Liver Failure and Advanced or Metastatic Solid Tumor that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 30 participants, below the 165-participant average among 7 other Liver Failure trials with a reported enrollment target (82% lower). The trial reports 13 study locations across 5 states.
The verdict
NCT04617522, a Phase 1 study of Liver Failure and Advanced or Metastatic Solid Tumor, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
Conditions Studied
Interventions
- DRUG Sacituzumab Govitecan-hziy
Study Locations (13)
Texas
- NEXT Austin - Austin
- Oncology Consultants, P.A. - Houston
- The University of Texas M.D. Anderson Cancer Center - Houston
- Texas Liver Institute - San Antonio
- NEXT Oncology - San Antonio
Other
- Institut Bergonie Medical Oncology - Bordeaux
- Centre Leon Berard - Lyon
- Institut de Cancerologie de l'Ouest (ICO) - Saint-Herblain - Saint-Herblain
- Institut Català d'Oncologia - L'Hospitalet de Llobregat - Barcelona
- Hospital Universitario Virgen del Rocío - Seville
California
- Pacific Shores Medical Group - Long Beach
Delaware
- Christiana Care Health Services - Newark
Maryland
- University of Maryland - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04617522
The ClinicalTrials.gov registry entry for NCT04617522 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 7 other Liver Failure trials with a reported enrollment target (82% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Liver Failure appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab Govitecan-hziy is the first listed.
NCT04617522 reports 13 study locations spanning 5 distinct geographic areas - top geographies include Texas, Other, California.
Frequently Asked Questions
What is clinical trial NCT04617522 about?
NCT04617522 is a clinical study titled "Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment". The goals of this clinical study are to learn more about the safety and dosing of the study drug, sacituzumab govitecan-hziy, in participants with solid tumors and moderate liver problems.
What is the current status of trial NCT04617522?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2021-04-06. Estimated completion is 2026-12.
What conditions does trial NCT04617522 study?
This clinical trial studies the following conditions: Liver Failure, Advanced or Metastatic Solid Tumor.
What interventions are being tested in trial NCT04617522?
The interventions under investigation include: Sacituzumab Govitecan-hziy (DRUG).
Who is sponsoring clinical trial NCT04617522?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04617522 being conducted?
This trial has 13 study locations across California, Delaware, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
ACTIVE NOT RECRUITING · Phase 1
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
-
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
COMPLETED · NA
-
A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
COMPLETED · Phase 2
-
Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.